ALB and neoplasm: Based on cytotoxicity and MDR-selectivity, [RhCp*­(BP)­Cl]­Clwas chosen for further nanoformulation studies using HSA, as a biocompatibleprotein-based carrier, and HSA combined with d-α-tocopherylpolyethylene glycol 1000 succinate (TPGS), which itself possessesanticancer effect,, and poly­(lactic-co-glycolic acid) (PLGA), with the aim of improving tumor-specificdelivery.